Deciphering OPA1 mutations pathogenicity by combined analysis of human,mouse and yeast cell models |
| |
Authors: | Valentina Del Dotto Mario Fogazza Francesco Musiani Alessandra Maresca Serena J. Aleo Leonardo Caporali Chiara La Morgia Cecilia Nolli Tiziana Lodi Paola Goffrini David Chan Valerio Carelli Michela Rugolo Enrico Baruffini Claudia Zanna |
| |
Affiliation: | 1. Unit of Neurology, Department of Biomedical and NeuroMotor Sciences (DIBINEM), University of Bologna, 40139 Bologna, Italy;2. Department of Pharmacy and Biotechnology (FABIT), University of Bologna, 40126 Bologna, Italy;3. IRCCS Institute of Neurological Sciences of Bologna, Bellaria Hospital, 40139 Bologna, Italy;4. Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, 43124 Parma, Italy;5. Division of Biology and Biological Engineering, California Institute of Technology (CALTECH), Pasadena, CA 91125, USA |
| |
Abstract: | OPA1 is the major gene responsible for Dominant Optic Atrophy (DOA) and the syndromic form DOA “plus”. Over 370 OPA1 mutations have been identified so far, although their pathogenicity is not always clear. We have analyzed one novel and a set of known OPA1 mutations to investigate their impact on protein functions in primary skin fibroblasts and in two “ad hoc” generated cell systems: the MGM1/OPA1 chimera yeast model and the Opa1?/? MEFs model expressing the mutated human OPA1 isoform 1. The yeast model allowed us to confirm the deleterious effects of these mutations and to gain information on their dominance/recessivity. The MEFs model enhanced the phenotypic alteration caused by mutations, nicely correlating with the clinical severity observed in patients, and suggested that the DOA “plus” phenotype could be induced by the combinatorial effect of mitochondrial network fragmentation with variable degrees of mtDNA depletion. Overall, the two models proved to be valuable tools to functionally assess and define the deleterious mechanism and the pathogenicity of novel OPA1 mutations, and useful to testing new therapeutic interventions. |
| |
Keywords: | OPA1 mutations Dominant Optic Atrophy (DOA) OPA1 Mitochondrial network mtDNA Mitochondrial functions |
本文献已被 ScienceDirect 等数据库收录! |
|